Description:
This is a phase 1, open-label, multicenter dose-escalation study to determine the RP2D of CI
8993 for administration to patients with relapsed/refractory solid tumors by evaluating the
safety and tolerability and characterizing the PK, PD, and anti cancer activity of CI-8993 in
this population.
Title
- Brief Title: Phase 1 Study of CI-8993 Anti-VISTA Antibody in Patients With Advanced Solid Tumor Malignancies
- Official Title: Phase 1 Study of CI-8993 Anti-VISTA Antibody in Patients With Advanced Solid Tumor Malignancies
Clinical Trial IDs
- ORG STUDY ID:
CI-8993-101
- NCT ID:
NCT04475523
Conditions
Interventions
Drug | Synonyms | Arms |
---|
CI-8993 | | CI-8993 dose escalation |
Purpose
This is a phase 1, open-label, multicenter dose-escalation study to determine the RP2D of CI
8993 for administration to patients with relapsed/refractory solid tumors by evaluating the
safety and tolerability and characterizing the PK, PD, and anti cancer activity of CI-8993 in
this population.
Detailed Description
The plan is to enroll approximately 50 patients with metastatic or unresectable solid tumor
malignancy (non-lymphoma) that is considered relapsed and/or refractory to prior therapy into
specific dose cohorts to determine the maximum tolerated dose (MTD) of full doses of CI-8993,
based on the occurrence of dose limiting toxicities (DLTs) 28 days from the first full dose.
Administration is every 2 weeks. To assure patient safety, each patient will receive an
initial low dose of CI-8993 (step-dose) one week prior to their first full dose.
A Safety Review Committee (SRC) will review all safety data and make cohort
escalation/de-escalation decisions.
Trial Arms
Name | Type | Description | Interventions |
---|
CI-8993 dose escalation | Experimental | Patients will be administered CI-8993 intravenously at a planned infusion rate over 2 hours at planned step-doses and subsequent full doses. The planned schedule of administration is every 2 weeks. The MTD of full doses of CI-8993 will be determined based on the occurrence of DLTs 28 days from the first full dose. Eligible patients may receive CI-8993 at the dose and schedule, according to their assigned cohorts, until disease progression or unacceptable toxicity. | |
Eligibility Criteria
Inclusion Criteria:
1. Patient must be ≥18 years of age
2. Patients must have the following disease related criteria:
- any type of solid tumor malignancy (non-lymphoma) that is metastatic or
unresectable and considered relapsed and/or refractory to prior therapy
- must have evaluable disease.
- Archival formalin-fixed, paraffin-embedded (FFPE) tumor tissue
3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
4. Adequate organ and bone marrow function, in the absence of growth factors.
5. Fertility criteria:
- Women of childbearing potential (WOCBP) and fertile males with WOCBP partners
must use highly effective contraception
- Women must agree not to donate eggs (ova, oocytes) for the purposes of assisted
reproduction
- Men must agree not to donate sperm
- A man who is sexually active with a woman of childbearing potential and has not
had a vasectomy must agree to use a highly effective method of birth control.
6. Patient must be willing and able to adhere to the prohibitions and restrictions
specified in the protocol. Due to the possibility of neurologic events, patient must
agree to refrain from driving or engaging in hazardous occupations or activities such
as operating heavy or dangerous machinery during the first cycle of treatment.
7. Each patient must sign an informed consent form (ICF) indicating that he or she
understands the purpose and procedures required for the study and is willing to
participate in the study.
8. Patient must have central venous access, such as port-a-cath, or peripherally inserted
central catheter for at least the first cycle of treatment.
Exclusion Criteria:
1. Patient has any of the following medical situations:
- Uncontrolled intercurrent illness including, but not limited to: poorly
controlled hypertension; poorly controlled diabetes; ongoing active infection
requiring antibiotics or acute infectious illness (including suspected viral
infection); symptomatic congestive heart failure; unstable angina pectoris;
cardiac arrhythmia considered to increase risk for the patient by the
Investigator; psychiatric illness that would limit compliance with study
requirement
- Medical illness requiring systemic glucocorticoid use > 10mg/day prednisone
equivalent.
- Patients with history of brain metastasis
- Personal or familial history of hemophagocytic lymphohistiocytosis or macrophage
activation syndrome
- An autoimmune disease with a history of flares requiring immunosuppressant
medications within the past 6 months
- History of known or suspected seizure disorder
- Prior allogeneic organ or bone marrow transplant (BMT).
- Social situation that would limit compliance with study requirements
- Major surgery (eg, requiring general anesthesia) within 4 weeks before the
planned first dose of study drug, or not fully recovered from prior surgery, or
has surgery planned during the time the patient is expected to participate in the
study or within 4 weeks after the last dose of study drug.
- History of positive testing for hepatitis B surface antigen (HBsAg) or hepatitis
C antibody (anti-hepatitis C virus) or other clinically active liver disease, or
positive testing at screening for HBsAg or anti- hepatitis C virus.
- History of human immunodeficiency virus (HIV) antibody positive
2. Patient has had prior therapy meeting the following:
- Anticancer immunotherapy within 3 weeks prior to the first dose of CI-8993
- Prior T Cell Receptor-modified or chimeric antigen receptor T cell (CART) therapy
- Other anticancer therapy, including chemotherapy, targeted therapy, or treatment
with an investigational anticancer agent within 2 weeks prior to the first dose
of CI-8993
- Radiotherapy (excluding limited palliative radiation) within 2 weeks of start of
CI-8993
- Unresolved toxicities from previous anticancer therapies above Grade 1.
- Immune-related AE with prior immunotherapy that was Grade 3 or higher.
- Patient has known allergies, hypersensitivity, or intolerance to components of CI
8993
3. Patient receiving therapeutic anticoagulants
4. Fertility exclusions:
- Patient is pregnant, breastfeeding, or planning to become pregnant while enrolled
in this study or within 3 months after the last dose of study drug; WOCBP must
have a negative pregnancy status confirmed by serum pregnancy test at screening
and within 72 hours of first dose of study drug.
- Patient is a man who plans to father a child while enrolled in this study or
within 3 months after the last dose of study drug.
5. Vaccinated with a live vaccine within 28 days (with the exception of the annual
inactivated influenza vaccine) prior to the first dose of study drug
Maximum Eligible Age: | N/A |
Minimum Eligible Age: | 18 Years |
Eligible Gender: | All |
Healthy Volunteers: | No |
Primary Outcome Measures
Measure: | To determine the maximum tolerated dose of CI-8993 |
Time Frame: | 2 years |
Safety Issue: | |
Description: | The highest dose at a schedule, at which the DLT rate during the first cycle of this study (28 days from the first full dose) is < 33% in at least 6 patients. |
Secondary Outcome Measures
Measure: | To characterize the pharmacokinetic (PK) parameters of CI-8993 measured by Cmax |
Time Frame: | 6 months |
Safety Issue: | |
Description: | maximum serum concentration (Cmax) |
Measure: | To characterize the pharmacokinetic (PK) parameters of CI-8993 measured by Cmin |
Time Frame: | 6 months |
Safety Issue: | |
Description: | trough serum concentration (Cmin) |
Measure: | To characterize the pharmacokinetic (PK) parameters of CI-8993 measured by Tmax |
Time Frame: | 6 months |
Safety Issue: | |
Description: | Time to maximum serum concentration |
Measure: | To characterize the pharmacokinetic (PK) parameters of CI-8993 measured by Area under the concentration versus time curve (AUC) |
Time Frame: | 6 months |
Safety Issue: | |
Description: | area under the concentration-time curve |
Measure: | To characterize the pharmacokinetic (PK) parameters of CI-8993 measured by T 1/2 |
Time Frame: | 6 months |
Safety Issue: | |
Description: | Serum terminal elimination half-life (T 1/2) |
Measure: | To characterize the pharmacokinetic (PK) parameters of CI-8993 measured by volume of distribution at steady state |
Time Frame: | 6 months |
Safety Issue: | |
Description: | volume of distribution at steady state (Vdss) |
Measure: | To characterize the pharmacokinetic (PK) parameters of CI-8993 measured by clearance |
Time Frame: | 6 months |
Safety Issue: | |
Description: | Clearance (CL) |
Measure: | To assess anti-drug antibodies (ADA) of CI-8993 |
Time Frame: | 6 months |
Safety Issue: | |
Description: | Evaluate antibodies to CI-8993 in serum |
Details
Phase: | Phase 1 |
Primary Purpose: | Interventional |
Overall Status: | Recruiting |
Lead Sponsor: | Curis, Inc. |
Last Updated
April 15, 2021